 |
|
|
|
|
Management Team
Argos' senior management has extensive pharmaceutical and biotechnology
industry experience including the clinical development, regulatory approval
and commercial introduction of successful oncology products.
|
| Jeffrey D. Abbey, M.B.A., J.D. |
President, Chief Executive Officer |
| Frederick M. Miesowicz, Ph.D. |
Chief Operating Officer |
| Charles A. Nicolette,
Ph.D. |
Chief Scientific Officer, Vice President, Research
and Development |
|
Jeffrey D. Abbey, M.B.A., J.D.
President and Chief Executive Officer
Jeffrey Abbey joined Argos Therapeutics in 2002. Before joining
Argos, Mr. Abbey was Vice President of Business Development and Finance
for Internet Appliance Network (IAN), a venture-backed information technology
company based in New York City. Prior to joining IAN, he was a partner
in Eilenberg and Krause, a boutique corporate law firm, where he acted
as business counsel for a number of life sciences and other emerging technology
companies. Mr. Abbey has extensive experience in structuring and negotiating
licenses, joint ventures and other technology transfer agreements, as well
as mergers, acquisitions and financing transactions. He holds an A.B. in
Mathematical Economics from Brown University and received an M.B.A. and
J.D. from the University of Virginia.
return to top
Frederick M. Miesowicz, Ph.D.
Chief Operating Officer
Frederick Miesowicz joined Argos Therapeutics in 2003. Prior to this,
Dr. Miesowicz was the Vice President of U.S. Operations for Gamida-Cell,
a stem cell company. He was Senior Vice President and General Manager of
Hybridon Specialty Products. He served as Vice President and General Manager
of Cellcor, a subsidiary of Cytogen, Inc., from 1995 to 1998, where he
directed all operations related to Cellcor’s cellular immunotherapy
programs. He also served as Senior Vice President of Scientific Affairs
at Cellcor from 1992 to 1995. Dr. Miesowicz has an extensive background
in cellular therapies and medical devices. Prior to joining Cellcor, he
managed the U.S. and European SteriCell Division of Terumo Medical Corporation
after it was acquired from DuPont, and was with E.I. DuPont de Nemours & Company
for over 14 years managing both immunotherapy and immunodiagnostic R&D
groups. Dr. Miesowicz holds a B.S. degree in Chemistry from Siena College
and received a Ph.D. in Chemistry from Harvard University.
return to top
Charles A. Nicolette, Ph.D.
Chief Scientific Officer and Vice President, Research and Development
Charles Nicolette joined Argos Therapeutics in 2003. Dr. Nicolette has extensive
experience in the field of cancer immunotherapy and is the inventor on dozens
of patent applications and issued patents relating to the development of personalized
immunotherapeutics for cancer and infectious diseases. He was formerly the Director
of Antigen Discovery at Genzyme Molecular Oncology where he developed SPHERE
technology, the subject of one of the largest biotechnology deals ever done in
the field of tumor antigen discovery. He is an expert in cellular immunology
and brings substantial immunological sophistication to Argos. Dr. Nicolette received
his Ph.D. in biochemistry and cellular and developmental biology from the State
University of New York at Stony Brook, completing his doctoral dissertation and
post-doctoral fellowship at Cold Spring Harbor Laboratory.
return to top
|
|
 |
|
